摘要
目的:系统评价ACEI/ARB联合中成药治疗早期糖尿病肾病的疗效及安全性。方法:通过PubMed、EMbase、The Cochrane Library、CNKI、Wanfang Data和VIP数据库,检索ACEI/ARB联合中成药治疗早期糖尿病肾病的随机对照实验,时限为建库至2018年7月。采用RevMan 5.3软件进行分析。结果:纳入27个RCTs,2 523例患者。Meta分析结果显示:ACEI/ARB联合中成药与单纯使用ACEI/ARB相比,临床显效率[ RR =1.94,95% CI(1.60,2.35)P <0.000 01];UAER[ MD =-20.55,95% CI(-24.22,-16.87),P <0.000 01];不良反应[ RR =1.06,95% CI(0.65,1.73),P =0.81]。结论:ACEI/ARB联合中成药可以更加降低尿蛋白,并不增加副反应。但是,本研究纳入的文献质量普遍不高,仍需要大样本多中心随机对照双盲实验来进一步证实。
Objective:To systematically evaluate the efficacy and safety of ACEI/ARB combined with traditional Chinese patent medicine(TCPM) for early DKD. Methods:Computer searches PubMed, EMbase, The Cochrane Library, CNKI, WanFang Data and VIP databases to collect RCTs on ACEI/ARB+TCPM and ACEI/ARB alone on early DKD. Time until July 2018. Use RevMan 5.3 software for analysis. Results:27 RCTs were included, including 2 523 patients. The clinically effective [ RR =1.94,95% CI (1.60,2.35), P <0.000 01];UAER[ MD =-20.55,95% CI (-24.22,-16.87), P <0.000 01];adverse events[ RR =1.06,95% CI (0.65,1.73), P =0.81]. Conclusion:ACEI/ARB+TCPM can significantly reduce UAER, and not increase adverse events. However, subject to the quantity and quality limitations of the included studies, more large-scale, high-quality RCTs are still needed to verify.
作者
杜华
柳诗意
石凯峰
孟祥飞
李玎玎
张宁
DU Hua;LIU Shiyi;SHI Kaifeng(Wangjing Hospital,Chinese Academy of Traditional Chinese Medicine,Beijing,100102)
出处
《中国中西医结合肾病杂志》
2019年第5期396-401,共6页
Chinese Journal of Integrated Traditional and Western Nephrology
基金
国家自然科学基金资助项目(No.81573949)
关键词
早期糖尿病肾病
中成药
ACEI/ARB联合中成药
系统评价
Early diabetic kidney disease
Chinese patent medicine
ACEI/ARB combined with Chinese patent medicine
Systematic reviews and meta-analysis
